{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T21:10:29Z","timestamp":1762809029123,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T00:00:00Z","timestamp":1611446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T00:00:00Z","timestamp":1611446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1038\/s41375-021-01129-0","type":"journal-article","created":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T11:02:27Z","timestamp":1611486147000},"page":"2435-2438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeting ubiquitin-specific protease-7 in plasmacytoid dendritic cells triggers anti-myeloma immunity"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0652-2905","authenticated-orcid":false,"given":"Arghya","family":"Ray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6729-2672","authenticated-orcid":false,"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara J.","family":"Buhrlage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5548-6138","authenticated-orcid":false,"given":"Dharminder","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-0886","authenticated-orcid":false,"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,24]]},"reference":[{"key":"1129_CR1","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","volume":"8","author":"RC Kane","year":"2003","unstructured":"Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8:508\u201313. https:\/\/doi.org\/10.1634\/theoncologist.8-6-508. PMID: 14657528","journal-title":"Oncologist"},{"key":"1129_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.6004\/jnccn.2013.0199","volume":"11","author":"KC Anderson","year":"2013","unstructured":"Anderson KC. Therapeutic advances in relapsed or refractory multiple myeloma. J Natl Compr Canc Netw. 2013;11:676\u20139.","journal-title":"J Natl Compr Canc Netw"},{"issue":"Apr","key":"1129_CR3","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/leu.2011.256","volume":"26","author":"NE Franke","year":"2012","unstructured":"Franke NE, Niewerth D, Assaraf YG, van Meerloo J, Vojtekova K, van Zantwijk CH, et al. Impaired bortezomib binding to mutant \u03b25 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia. 2012;26(Apr):757\u201368. https:\/\/doi.org\/10.1038\/leu.2011.256. Epub 2011 Sep 23PMID: 21941364.","journal-title":"Leukemia"},{"key":"1129_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","volume":"18","author":"D Niewerth","year":"2015","unstructured":"Niewerth D, Jansen G, Assaraf YG, Zweegman S, Kaspers GJ, Cloos J. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist Update. 2015;18:18\u201335. https:\/\/doi.org\/10.1016\/j.drup.2014.12.001. PMID: 25670156","journal-title":"Drug Resist Update"},{"issue":"Mar","key":"1129_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/2050-7771-1-13","volume":"1","author":"S L\u00fc","year":"2013","unstructured":"L\u00fc S, Wang J. The resistance mechanisms of proteasome inhibitor bortezomib. Biomark Res. 2013;1(Mar):13 https:\/\/doi.org\/10.1186\/2050-7771-1-13. PMID: 24252210; PMCID: PMC4177604.","journal-title":"Biomark Res"},{"issue":"Jan","key":"1129_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1073\/pnas.1619067114","volume":"114","author":"P Tsvetkov","year":"2017","unstructured":"Tsvetkov P, Sokol E, Jin D, Brune Z, Thiru P, Ghandi M, et al. Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers. Proc Natl Acad Sci USA. 2017;114(Jan):382\u20137. https:\/\/doi.org\/10.1073\/pnas.1619067114. Epub 2016 Dec 27PMID: 28028240; PMCID: PMC5240730.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1129_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","volume":"22","author":"D Chauhan","year":"2012","unstructured":"Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012;22:345\u201358. PMID: 22975377; PMCID: PMC3478134","journal-title":"Cancer Cell"},{"issue":"Oct","key":"1129_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","volume":"16","author":"D Chauhan","year":"2009","unstructured":"Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009;16(Oct):309\u201323. https:\/\/doi.org\/10.1016\/j.ccr.2009.08.019. PMID: 19800576; PMCID: PMC2762396","journal-title":"Cancer Cell"},{"issue":"Jun","key":"1129_CR9","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2015.11","volume":"29","author":"A Ray","year":"2015","unstructured":"Ray A, Das DS, Song Y, Richardson P, Munshi NC, Chauhan D, et al. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia. 2015;29(Jun):1441\u20134. https:\/\/doi.org\/10.1038\/leu.2015.11. Epub 2015 Jan 30. PMID: 25634684; PMCID: PMC5703039","journal-title":"Leukemia"},{"issue":"Aug","key":"1129_CR10","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/leu.2014.46","volume":"28","author":"A Ray","year":"2014","unstructured":"Ray A, Tian Z, Das DS, Coffman RL, Richardson P, Chauhan D. et al. A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib. Leukemia. 2014;28(Aug):1716\u201324. https:\/\/doi.org\/10.1038\/leu.2014.46. Epub 2014 Jan 30. PMID: 24476765; PMCID: PMC4116471.","journal-title":"Leukemia"},{"issue":"Mar","key":"1129_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-62076-x","volume":"10","author":"NJ Schauer","year":"2020","unstructured":"Schauer NJ, Liu X, Magin RS, Doherty LM, Chan WC, Ficarro SB, et al. Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. Sci Rep. 2020;10(Mar):5324 https:\/\/doi.org\/10.1038\/s41598-020-62076-x. PMID: 32210275; PMCID: PMC7093416","journal-title":"Sci Rep"},{"issue":"Nov","key":"1129_CR12","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3389\/fimmu.2017.01444","volume":"8","author":"G Pittari","year":"2017","unstructured":"Pittari G, Vago L, Festuccia M, Bonini C, Mudawi D, Giaccone L, et al. Restoring natural killer cell immunity against multiple myeloma in the era of new drugs. Front Immunol. 2017;8(Nov):1444 https:\/\/doi.org\/10.3389\/fimmu.2017.01444. PMID: 29163516; PMCID: PMC5682004","journal-title":"Front Immunol"},{"issue":"May","key":"1129_CR13","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1600-065X.2011.01018.x","volume":"241","author":"AY Rudensky","year":"2011","unstructured":"Rudensky AY. Regulatory T cells and Foxp3. Immunol Rev. 2011;241(May):260\u20138. https:\/\/doi.org\/10.1111\/j.1600-065X.2011.01018.x. PMID: 21488902; PMCID: PMC3077798","journal-title":"Immunol Rev"},{"issue":"Jun","key":"1129_CR14","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1158\/0008-5472.CAN-17-3102","volume":"78","author":"S Hibino","year":"2018","unstructured":"Hibino S, Chikuma S, Kondo T, Ito M, Nakatsukasa H, Omata-Mise S, et al. Inhibition of Nr4a receptors enhances antitumor immunity by breaking Treg-mediated immune tolerance. Cancer Res. 2018;78(Jun):3027\u201340. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-3102. Epub2018 Mar 20. PMID: 29559474.","journal-title":"Cancer Res"},{"issue":"Jul","key":"1129_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.celrep.2017.06.062","volume":"20","author":"JE Jang","year":"2017","unstructured":"Jang JE, Hajdu CH, Liot C, Miller G, Dustin ML, Bar-Sagi D. Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer. Cell Rep. 2017;20(Jul):558\u201371. https:\/\/doi.org\/10.1016\/j.celrep.2017.06.062. PMID: 28723561; PMCID: PMC5649374","journal-title":"Cell Rep"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-021-01129-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-021-01129-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-021-01129-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:41:54Z","timestamp":1684618914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01129-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,24]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1129"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01129-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"type":"print","value":"0887-6924"},{"type":"electronic","value":"1476-5551"}],"subject":[],"published":{"date-parts":[[2021,1,24]]},"assertion":[{"value":"6 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KCA is on Advisory Boards of Millenium-Takeda, Gilead, Janssen, Sanofi-Aventis, and Bristol Myers Squibb; and is a Scientific Founder of Oncopep and C4 Therapeutics. DC is a consultant to Stemline Therapeutics, Inc., Oncopeptide AB, and an Equity owner in C4 Therapeutics. The remaining authors declare no conflict of interest. Other authors have no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}